Skip to main content
main-content

02-06-2019 | Breast cancer | Video

ASCO 2019: Ribociclib addition boosts OS in premenopausal advanced breast cancer patients

Sara Hurvitz summarises the findings of the phase III MONALEESA-7 trial investigating the addition of ribociclib to endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (3:21).

Funding for this video was provided in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland.